NASDAQ · TCBPW
TC Biopharm (Holdings) Plc
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 2:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.28K
- P/E ratio
- -0.04
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 452.61K
- Avg. volume
- 44.03K
Price performance
TCBPW price history
1M range · 0 trading sessions · Daily adjusted prices
TCBPW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest TCBPW news
The latest Smart Investors Daily articles mentioning TCBPW.
Stock researchCompany · Overview
TCBPW research
Overview
Company profile and research snapshot.
Company profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
